Red blood cell transfusion thresholds and Quality of Life in myelodysplastic syndromes: a pilot, feasibility study

HS Blood and Transplant (NHSBT)0 个研究点目标入组 38 人开始时间: 2014年11月13日最近更新: 2021年2月8日

适应症

试验速览

•1. All patients with MDS =18 years of age and with < 20% blasts on bone marrow aspirate (WHO classification), including non-proliferative CMML and other MDS/MPN overlap diseases. These patients will include both those recently diagnosed and with an established diagnosis
•2. Transfusion dependent: at least 1 red cell transfusion episode per month in the last 8 weeks
•3. Life expectancy >6 months

•1 .Unable, in the opinion of the attending clinician, to tolerate restrictive or liberal red cell transfusion thresholds (e.g. clinically significant cardio-respiratory compromise)
•2. Poor performance/functional status (Eastern Cooperative Oncology Group system ECOG =3)
•3. Patients being actively treated with erythropiesis stimulating agents (ESAs) or disease modifying agents for their MDS (such as lenalidomide, azacitidine, hydroxycarbamide, experimental agents), as these may exert their own effects on the patients' quality of life and may render patients transfusion independent
•4. Patients with myelofibrosis
•5. Patients in whom the attending clinician considers that active bleeding or ongoing haemolysis contribute significantly to the cause of anaemia
•6. Patients presenting with splenomegaly >5cm below the costal margin

发起方

HS Blood and Transplant (NHSBT)